Research programme: anti-CD38 human monoclonal antibodies - Crucell
Alternative Names: Anti-CD38 human monoclonal antibodies research programme - CrucellLatest Information Update: 27 Jan 2005
At a glance
- Originator Crucell
- Class
- Mechanism of Action CD38 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Autoimmune disorders; Multiple myeloma
Most Recent Events
- 27 Jan 2005 Discontinued - Preclinical for Autoimmune disorders in Netherlands (unspecified route)
- 27 Jan 2005 Discontinued - Preclinical for Multiple myeloma in Netherlands (unspecified route)
- 11 Feb 2002 Preclinical development for Autoimmune disorders in Netherlands (Unknown route)